Head and Neck Cancer Therapeutics Global Market Report 2024

The head and neck cancer therapeutics market size has grown rapidly in recent years. It will grow from $1.55 billion in 2023 to $1.73 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth observed in previous periods can be attributed to increased sales in the tobacco and alcohol industries, rising cases of human papillomavirus (HPV) infections, environmental exposures, and advancements in treatment methods.

The head and neck cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The projected growth can be credited to advancements in immunotherapy, the adoption of precision medicine strategies, increased awareness through early diagnosis initiatives, and the expanding aging population worldwide. Key trends in the forecast period encompass the growing utilization of targeted therapies, the integration of minimally invasive surgical methods, the incorporation of palliative care, exploration into new biomarkers, and the implementation of patient-centric care models.

The rising prevalence of head and neck cancer is anticipated to drive the growth of the head and neck cancer therapeutics market. This medical condition involves the uncontrolled growth of cells in the tissues of the head and neck region, necessitating improved diagnostic and treatment options to address mutations and abnormalities in cancer cells. In 2023, projections from Cancer Research UK indicate a 3% increase in the incidence of head and neck cancer in the UK between 2023 and 2025. Additionally, deaths attributed to head and neck cancers are expected to rise by 12% during the same period, underscoring the growing need for effective therapeutic interventions.

The consumption of tobacco and alcohol at high levels is expected to contribute to the expansion of the head and neck cancer therapeutics market. Habitual use of tobacco products and alcoholic beverages exposes the lining of the mouth, throat, larynx, and other areas to carcinogenic substances, leading to an increased risk of head and neck cancer. Notably, in August 2023, the American Academy of Family Physicians reported a significant surge in e-cigarette unit sales, rising by over 46% from January 2020 to December 2022. This increase, along with a rise in e-cigarette use among U.S. adults to 6% in 2022 from 3.7% in 2020, emphasizes the impact of high tobacco consumption on the prevalence of head and neck cancer, thereby driving the demand for therapeutic solutions.

Leading companies in the head and neck cancer therapeutics market are focused on introducing novel drug treatments to address the needs of patients with head and neck cancer. Drug treatment involves the use of pharmaceutical substances to manage or alleviate medical conditions, and in October 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, achieved FDA approval for its latest drug, 'Loqtorzi' (toripalimab-tpzi). The approval allows for the use of the drug in combination with cisplatin and gemcitabine as the initial treatment for adults diagnosed with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The clinical trial demonstrated favorable results, with adverse reactions occurring in fewer than 20% of patients, whether used as a first-line option or as a single-agent therapy.

Major players in the head and neck cancer therapeutics market are also dedicated to developing innovative solutions, such as AI-enabled MR (Magnetic Resonance) imaging. This approach involves incorporating artificial intelligence (AI) technology into the MR process, optimizing various aspects from image acquisition to interpretation. In October 2022, Koninklijke Philips N.V., a Netherlands-based health technology company, received FDA approval for two advances in MR-only workflows such as (AI)-enabled MRCAT Head and Neck' and 'MacroMedics.' The (AI)-enabled MRCAT Head and Neck radiotherapy application facilitates the use of MR as the exclusive or primary imaging modality for planning radiotherapy, especially for soft tissue tumors located in the head and neck, as well as in the brain, pelvis, and prostate.

In March 2023, InvoX Pharma Ltd., a UK-based biopharmaceutical company, completed the acquisition of F-star Therapeutics Inc. for a sum of $161 million. This strategic move fortified InvoX Pharma's standing in the cancer therapeutics sector, expanding its portfolio and broadening its market reach. F-star Therapeutics Inc., based in the US, specializes in clinical-stage biopharmaceuticals, particularly focusing on head and neck cancer immunotherapy.

Major companies operating in the head and neck cancer therapeutics market report are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.

North America was the largest region in the head and neck cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of head and neck cancer therapeutics are programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. PD inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, function by obstructing interactions between PD-1 and its ligands, PD-L1 and PD-L2, present in certain cancer cells. These medications are administered through injectable or oral routes and are available through multiple distribution channels such as retail and specialty pharmacies, hospital pharmacies, and online pharmacies. They find application in surgery, radiation therapy, chemotherapy, immunotherapy, and other treatment modalities.

The head and neck cancer therapeutics research report is one of a series of new reports that provides head and neck cancer therapeutics market statistics, including the head and neck cancer therapeutics industry's global market size, regional shares, competitors with head and neck cancer therapeutics market share, detailed head and neck cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer therapeutics industry. This head and neck cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The head and neck cancer therapeutics market consists of sales of bleomycin sulfate, cetuximab, docetaxel, and erbitux. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.